Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 944-948, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-880297
ABSTRACT
Prostate cancer (PCa) has become one of the common malignant diseases in elderly men, and its incidence is increasing year by year. Apart from surgery, radiotherapy and chemotherapy, immunotherapy, as with the programmed death receptor-1 (PD-1) or the programmed death ligand-1 (PD-L1) inhibitor, is a most promising new strategy for the treatment of PCa. PD-1 and PD-L1 inhibitors restore the activity of T cells by blocking the PD-1/PD-L1 signaling pathway in tumor cells, reverse the mechanism of tumor immune escape, recover the immune system and directly kill tumor cells. This review focuses on the current progress in the studies of PD-1 and PD-L1 inhibitors in the treatment of PCa.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostatic Neoplasms
/
Signal Transduction
/
B7-H1 Antigen
/
Programmed Cell Death 1 Receptor
/
Immune Checkpoint Inhibitors
/
Immunotherapy
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS